All these results indicate that circCDYL2 contributes to trastuzumab resistance of HER2+-breast cancer, either FAK inhibitor or GRB7 inhibitor reduces circCDYL2-induced trastuzumab resistance through the activation of PI3K/AKT and MERK/ERK pathways. This evidence concerns the gene ERBB2 and breast cancer.